CSF and blood levels of GFAP in Alexander disease

Paige L. Jany, Guillermo E. Agosta, William S. Benko, Jens C. Eickhoff, Stephanie R. Keller, Wolfgang Köehler, David Koeller, Soe Mar, Sakkubai Naidu, Jayne Marie Ness, Davide Pareyson, Deborah L. Renaud, Ettore Salsano, Raphael Schiffmann, Julie Simon, Adeline Vanderver, Florian Eichler, Marjo S. van der Knaap, Albee Messing

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Alexander disease is a rare, progressive, and generally fatal neurological disorder that results from dominant mutations affecting the coding region of GFAP, the gene encoding glial fibrillary acidic protein, the major intermediate filament protein of astrocytes in the CNS. A key step in pathogenesis appears to be the accumulation of GFAP within astrocytes to excessive levels. Studies using mouse models indicate that the severity of the phenotype correlates with the level of expression, and suppression of GFAP expression and/or accumulation is one strategy that is being pursued as a potential treatment. With the goal of identifying biomarkers that indirectly reflect the levels of GFAP in brain parenchyma, we have assayed GFAP levels in two body fluids in humans that are readily accessible as biopsy sites: CSF and blood. We find that GFAP levels are consistently elevated in the CSF of patients with Alexander disease, but only occasionally and modestly elevated in blood. These results provide the foundation for future studies that will explore whether GFAP levels can serve as a convenient means to monitor the progression of disease and the response to treatment.

Original languageEnglish (US)
Article numbere0080-15.2015
JournaleNeuro
Volume2
Issue number5
DOIs
StatePublished - Jan 1 2015

Fingerprint

Alexander Disease
Astrocytes
Intermediate Filament Proteins
Glial Fibrillary Acidic Protein
Body Fluids
Nervous System Diseases
Disease Progression
Biomarkers
Phenotype
Biopsy
Mutation
Brain
Therapeutics
Genes

Keywords

  • Astrocyte
  • Biomarker
  • GFAP

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Jany, P. L., Agosta, G. E., Benko, W. S., Eickhoff, J. C., Keller, S. R., Köehler, W., ... Messing, A. (2015). CSF and blood levels of GFAP in Alexander disease. eNeuro, 2(5), [e0080-15.2015]. https://doi.org/10.1523/ENEURO.0080-15.2015

CSF and blood levels of GFAP in Alexander disease. / Jany, Paige L.; Agosta, Guillermo E.; Benko, William S.; Eickhoff, Jens C.; Keller, Stephanie R.; Köehler, Wolfgang; Koeller, David; Mar, Soe; Naidu, Sakkubai; Ness, Jayne Marie; Pareyson, Davide; Renaud, Deborah L.; Salsano, Ettore; Schiffmann, Raphael; Simon, Julie; Vanderver, Adeline; Eichler, Florian; van der Knaap, Marjo S.; Messing, Albee.

In: eNeuro, Vol. 2, No. 5, e0080-15.2015, 01.01.2015.

Research output: Contribution to journalArticle

Jany, PL, Agosta, GE, Benko, WS, Eickhoff, JC, Keller, SR, Köehler, W, Koeller, D, Mar, S, Naidu, S, Ness, JM, Pareyson, D, Renaud, DL, Salsano, E, Schiffmann, R, Simon, J, Vanderver, A, Eichler, F, van der Knaap, MS & Messing, A 2015, 'CSF and blood levels of GFAP in Alexander disease', eNeuro, vol. 2, no. 5, e0080-15.2015. https://doi.org/10.1523/ENEURO.0080-15.2015
Jany PL, Agosta GE, Benko WS, Eickhoff JC, Keller SR, Köehler W et al. CSF and blood levels of GFAP in Alexander disease. eNeuro. 2015 Jan 1;2(5). e0080-15.2015. https://doi.org/10.1523/ENEURO.0080-15.2015
Jany, Paige L. ; Agosta, Guillermo E. ; Benko, William S. ; Eickhoff, Jens C. ; Keller, Stephanie R. ; Köehler, Wolfgang ; Koeller, David ; Mar, Soe ; Naidu, Sakkubai ; Ness, Jayne Marie ; Pareyson, Davide ; Renaud, Deborah L. ; Salsano, Ettore ; Schiffmann, Raphael ; Simon, Julie ; Vanderver, Adeline ; Eichler, Florian ; van der Knaap, Marjo S. ; Messing, Albee. / CSF and blood levels of GFAP in Alexander disease. In: eNeuro. 2015 ; Vol. 2, No. 5.
@article{30ec22b8a62e42d4a4d34eb846599d30,
title = "CSF and blood levels of GFAP in Alexander disease",
abstract = "Alexander disease is a rare, progressive, and generally fatal neurological disorder that results from dominant mutations affecting the coding region of GFAP, the gene encoding glial fibrillary acidic protein, the major intermediate filament protein of astrocytes in the CNS. A key step in pathogenesis appears to be the accumulation of GFAP within astrocytes to excessive levels. Studies using mouse models indicate that the severity of the phenotype correlates with the level of expression, and suppression of GFAP expression and/or accumulation is one strategy that is being pursued as a potential treatment. With the goal of identifying biomarkers that indirectly reflect the levels of GFAP in brain parenchyma, we have assayed GFAP levels in two body fluids in humans that are readily accessible as biopsy sites: CSF and blood. We find that GFAP levels are consistently elevated in the CSF of patients with Alexander disease, but only occasionally and modestly elevated in blood. These results provide the foundation for future studies that will explore whether GFAP levels can serve as a convenient means to monitor the progression of disease and the response to treatment.",
keywords = "Astrocyte, Biomarker, GFAP",
author = "Jany, {Paige L.} and Agosta, {Guillermo E.} and Benko, {William S.} and Eickhoff, {Jens C.} and Keller, {Stephanie R.} and Wolfgang K{\"o}ehler and David Koeller and Soe Mar and Sakkubai Naidu and Ness, {Jayne Marie} and Davide Pareyson and Renaud, {Deborah L.} and Ettore Salsano and Raphael Schiffmann and Julie Simon and Adeline Vanderver and Florian Eichler and {van der Knaap}, {Marjo S.} and Albee Messing",
year = "2015",
month = "1",
day = "1",
doi = "10.1523/ENEURO.0080-15.2015",
language = "English (US)",
volume = "2",
journal = "eNeuro",
issn = "2373-2822",
publisher = "Society for Neuroscience",
number = "5",

}

TY - JOUR

T1 - CSF and blood levels of GFAP in Alexander disease

AU - Jany, Paige L.

AU - Agosta, Guillermo E.

AU - Benko, William S.

AU - Eickhoff, Jens C.

AU - Keller, Stephanie R.

AU - Köehler, Wolfgang

AU - Koeller, David

AU - Mar, Soe

AU - Naidu, Sakkubai

AU - Ness, Jayne Marie

AU - Pareyson, Davide

AU - Renaud, Deborah L.

AU - Salsano, Ettore

AU - Schiffmann, Raphael

AU - Simon, Julie

AU - Vanderver, Adeline

AU - Eichler, Florian

AU - van der Knaap, Marjo S.

AU - Messing, Albee

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Alexander disease is a rare, progressive, and generally fatal neurological disorder that results from dominant mutations affecting the coding region of GFAP, the gene encoding glial fibrillary acidic protein, the major intermediate filament protein of astrocytes in the CNS. A key step in pathogenesis appears to be the accumulation of GFAP within astrocytes to excessive levels. Studies using mouse models indicate that the severity of the phenotype correlates with the level of expression, and suppression of GFAP expression and/or accumulation is one strategy that is being pursued as a potential treatment. With the goal of identifying biomarkers that indirectly reflect the levels of GFAP in brain parenchyma, we have assayed GFAP levels in two body fluids in humans that are readily accessible as biopsy sites: CSF and blood. We find that GFAP levels are consistently elevated in the CSF of patients with Alexander disease, but only occasionally and modestly elevated in blood. These results provide the foundation for future studies that will explore whether GFAP levels can serve as a convenient means to monitor the progression of disease and the response to treatment.

AB - Alexander disease is a rare, progressive, and generally fatal neurological disorder that results from dominant mutations affecting the coding region of GFAP, the gene encoding glial fibrillary acidic protein, the major intermediate filament protein of astrocytes in the CNS. A key step in pathogenesis appears to be the accumulation of GFAP within astrocytes to excessive levels. Studies using mouse models indicate that the severity of the phenotype correlates with the level of expression, and suppression of GFAP expression and/or accumulation is one strategy that is being pursued as a potential treatment. With the goal of identifying biomarkers that indirectly reflect the levels of GFAP in brain parenchyma, we have assayed GFAP levels in two body fluids in humans that are readily accessible as biopsy sites: CSF and blood. We find that GFAP levels are consistently elevated in the CSF of patients with Alexander disease, but only occasionally and modestly elevated in blood. These results provide the foundation for future studies that will explore whether GFAP levels can serve as a convenient means to monitor the progression of disease and the response to treatment.

KW - Astrocyte

KW - Biomarker

KW - GFAP

UR - http://www.scopus.com/inward/record.url?scp=85016565909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016565909&partnerID=8YFLogxK

U2 - 10.1523/ENEURO.0080-15.2015

DO - 10.1523/ENEURO.0080-15.2015

M3 - Article

VL - 2

JO - eNeuro

JF - eNeuro

SN - 2373-2822

IS - 5

M1 - e0080-15.2015

ER -